Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This randomized prospective study aims to determine the effect of ketorolac on the total dose of morphine required to achieve postoperative analgesia in children with obstructive sleep apnea (OSA) undergoing adenotonsillectomy. Participants will be randomly assigned to a study group where they will receive ketorolac in addition to the standard of care treatment or will receive only the standard of care pain management. The researchers hypothesize that by administering ketorolac at the end of the procedure once hemostasis has been achieved, it will be possible to decrease the amount of morphine administered in the post-anesthesia care unit (PACU). This study aims to provide a more comprehensive understanding of the efficacy and safety of the current standard post-operative analgesic regimen employed at the study institution, in which opioid analgesia currently plays a prominent role.
Obstructive sleep apnea (OSA) as an indication for adenotonsillectomy has increased significantly over the past ten years, and now has surpassed recurrent tonsillitis as the most common indication for this procedure. Opioids continue to be the most commonly administered pain medication for these procedures. Studies have shown that patients with OSA have significantly increased sensitivity to opioids that results in post-operative respiratory depression and apnea when administered via standard opioid dosing protocols. Children with OSA were shown to have a nearly fivefold increase in the odds of developing respiratory complications when compared to their counterparts with tonsillitis. Ketorolac possesses similar efficacy to morphine without the problematic complications of respiratory depression, nausea and vomiting, which are commonly seen post-adenotonsillectomy. Importantly, when combined with opioids, ketorolac is opioid-sparing. This synergistic effect means that a similar level of analgesia is achieved using a lower dose of opioid. However, there continues to be concern about using ketorolac due to the potential risk of post-operative bleeding from anti-platelet activity.
This randomized, prospective study aims to determine the effect of ketorolac on the total dose of morphine required to achieve postoperative analgesia in children with OSA undergoing adenotonsillectomy. Participants will be randomly assigned to receive ketorolac or to not receive ketorolac. The post-anesthesia care unit (PACU) nurses, who will be blinded to ketorolac administration, will evaluate the patients using the Face, Legs, Activity, Cry, Consolability (FLACC) scale scores at 10 minutes post-op, 20 minutes post-op and at time of PACU discharge. For patients with a FLACC score of 6-10, morphine (0.05mg/kg) will be administered. For patients with FLACC scores of 3-5, morphine (0.025mg/kg) will be administered. The total amount of opioid required to obtain a FLACC score of less than 3 will be evaluated as the primary outcome. The secondary outcomes to be evaluated will be PACU FLACC scores, time required in PACU, incidence of post-tonsillectomy bleeding and total pain medications administered during hospital admission.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Ketorolac | Experimental | Participants randomized to the ketorolac group will receive 0.5mg/kg IV at the end of the adenotonsillectomy procedure, once hemostasis has been achieved |
|
| Standard of Care | Active Comparator | Participants randomized to this group will receive the pain management standard of care for the adenotonsillectomy procedure. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Ketorolac | Drug | Patients in this group will receive 0.5mg/kg of ketorolac, administered intravenously. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Post-Anesthesia Care Unit (PACU) Morphine Requirements | The total postoperative morphine dosage required to achieve analgesia (defined as a Face, Legs, Activity, Cry, Consolability (FLACC) Scale score of less than 3) in children with obstructive sleep apnea undergoing adenotonsillectomy was compared between study arms to examine the effect of ketorolac administration. | Until PACU discharge (up to 261 minutes) |
| Measure | Description | Time Frame |
|---|---|---|
| Face, Legs, Activity, Cry, Consolability (FLACC) Scale Score | Post-Anesthesia Care Unit (PACU) nurses evaluated the patients using Face, Legs, Activity, Cry, Consolability (FLACC) Scale scores at 10 minutes post-op, 20 minutes post-op and at time of PACU discharge. Each category is scored as 0 (no indication of pain), 1 (indication of moderate pain), or 2 (visibly experiencing severe pain). Total scores range from 0 to 10, with higher scores indicating more pain. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Laura Gilbertson, MD | Emory University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Childrens Healthcare of Atlanta, Egleston | Atlanta | Georgia | 30322 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Participants were recruited from Children's Healthcare of Atlanta at Egleston in Atlanta, Georgia, USA. Participant enrollment began July 19, 2018 and the final study assessment occurred on August 22, 2023.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Ketorolac | Participants randomized to the ketorolac group received 0.5mg/kg IV at the end of the adenotonsillectomy procedure, once hemostasis was achieved. Ketorolac: Patients in this group received 0.5mg/kg of ketorolac, administered intravenously. Standard of Care: All patients underwent inhalational induction with nitrous oxide and sevoflurane. After intravenous (IV) placement, 1-3mg/kg of propofol and 1mcg/kg of fentanyl were administered. After induction, 0.5mg/kg of dexamethasone and an IV infusion of 15mg/kg of acetaminophen were administered. During surgery, 0.5mcg/kg of dexmedetomidine and 0.1mg/kg ondansetron were given. A rescue dose of 0.5-1mcg/kg of IV Fentanyl was available for use at the end of the procedure. The decision to administer was left to the discretion of the attending anesthesiologist. The choice to give this was made based on variables including patient's condition and a 20% increase in the heart rate and blood pressure. The PACU nurses, who were blinded to ketorolac administration, evaluated the patients using FLACC scores. For patients with a FLACC score of 6-10, morphine 0.05mg/kg was administered. For patients with FLACC scores of 3-5, morphine 0.025mg/kg was administered. |
| FG001 | Standard of Care | Participants randomized to this group received the pain management standard of care for the adenotonsillectomy procedure. Standard of Care: All patients underwent inhalational induction with nitrous oxide and sevoflurane. After intravenous (IV) placement, 1-3mg/kg of propofol and 1mcg/kg of fentanyl were administered. After induction, 0.5mg/kg of dexamethasone and an IV infusion of 15mg/kg of acetaminophen were administered. During surgery, 0.5mcg/kg of dexmedetomidine and 0.1mg/kg ondansetron were given. A rescue dose of 0.5-1mcg/kg of IV Fentanyl was available for use at the end of the procedure. The decision to administer was left to the discretion of the attending anesthesiologist. The choice to give this was made based on variables including patient's condition and a 20% increase in the heart rate and blood pressure. The PACU nurses, who were blinded to ketorolac administration, evaluated the patients using FLACC scores. For patients with a FLACC score of 6-10, morphine 0.05mg/kg was administered. For patients with FLACC scores of 3-5, morphine 0.025mg/kg was administered. |
| Title | Milestones | Reasons Not Completed | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Ketorolac | Participants randomized to the ketorolac group received 0.5mg/kg IV at the end of the adenotonsillectomy procedure, once hemostasis was achieved. |
| BG001 | Standard of Care |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Post-Anesthesia Care Unit (PACU) Morphine Requirements | The total postoperative morphine dosage required to achieve analgesia (defined as a Face, Legs, Activity, Cry, Consolability (FLACC) Scale score of less than 3) in children with obstructive sleep apnea undergoing adenotonsillectomy was compared between study arms to examine the effect of ketorolac administration. | This analysis includes participants who completed the study. | Posted | Mean | Standard Deviation | mg/kg | Until PACU discharge (up to 261 minutes) |
|
Information on adverse events was collected among participants who completed the surgery, beginning at the time of consent and continued through the final assessment at complete recovery, up to 14 days after surgery.
Post-tonsillectomy bleeding requiring surgery is a known risk of tonsillectomy and is not considered to be a serious adverse event in this study.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Ketorolac | Participants randomized to the ketorolac group received 0.5mg/kg IV at the end of the adenotonsillectomy procedure, once hemostasis was achieved. |
Not provided
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Post-operative bleeding requiring surgery | Injury, poisoning and procedural complications | Non-systematic Assessment |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Dr. Laura Gilbertson | Emory University | 404-785-6670 | laura.gilbertson@emory.edu |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | Apr 20, 2022 | Aug 5, 2024 | Prot_SAP_000.pdf |
Not provided
| ID | Term |
|---|---|
| D020181 | Sleep Apnea, Obstructive |
| D010149 | Pain, Postoperative |
| ID | Term |
|---|---|
| D012891 | Sleep Apnea Syndromes |
| D001049 | Apnea |
| D012120 | Respiration Disorders |
| D012140 | Respiratory Tract Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D020910 | Ketorolac |
| D020911 | Ketorolac Tromethamine |
| D059039 | Standard of Care |
| D000077149 | Sevoflurane |
| D015742 | Propofol |
| D002123 | Calcium Dobesilate |
| D020927 | Dexmedetomidine |
| D017294 | Ondansetron |
| D009020 | Morphine |
| ID | Term |
|---|---|
| D007213 | Indomethacin |
| D007211 | Indoles |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
Not provided
Not provided
Not provided
Not provided
Not provided
The PACU nurses will be blinded to ketorolac administration, but will be informed of all other medications given. The PACU nurses will evaluate the patients using FLACC scores at 10 minutes post-op, 20 minutes post-op and at time of PACU discharge. Morphine will be administered to obtain a FLACC score of less than 3.
| Standard of Care | Drug | All patients will undergo inhalational induction with nitrous oxide and sevoflurane. After intravenous (IV) placement, 1-3mg/kg of propofol and 1mcg/kg of fentanyl will be administered. After induction, 0.5mg/kg of dexamethasone and an IV infusion of 15mg/kg of acetaminophen will be administered. During surgery, 0.5mcg/kg of dexmedetomidine and 0.1mg/kg ondansetron will be given. A rescue dose of 0.5-1mcg/kg of IV Fentanyl will be available for use at the end of the procedure. The decision to administer will be left to the discretion of the attending anesthesiologist. The choice to give this will be made based on variables including patient's condition and a 20% increase in the heart rate and blood pressure. The PACU nurses, who will be blinded to ketorolac administration, will evaluate the patients using FLACC scores. For patients with a FLACC score of 6-10, morphine 0.05mg/kg will be administered. For patients with FLACC scores of 3-5, morphine 0.025mg/kg will be administered. |
|
|
| 10 minutes post-op, 20 minutes post-op, PACU discharge (up to 261 minutes) |
| Post-Anesthesia Care Unit (PACU) Recovery Time | The duration of time that a participant was in the Post-Anesthesia Care Unit (PACU), following surgery, measured in minutes. | Until PACU discharge (up to 261 minutes) |
| Number of Participants With Post-Tonsillectomy Bleeding | Participants were monitored via medical chart review for post-tonsillectomy bleeding. | Up to 14 days after surgery |
| Pain Medication Administration | The total amount of pain medications administered during hospitalization was examined. | Surgery through hospital discharge (up to post-operative day 2) |
| Withdrawal by Subject |
|
Participants randomized to this group received the pain management standard of care for the adenotonsillectomy procedure.
| BG002 | Total | Total of all reporting groups |
| years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Race (NIH/OMB) | Count of Participants | Participants |
|
| Region of Enrollment | Number | participants |
|
Participants randomized to this group received the pain management standard of care for the adenotonsillectomy procedure. |
|
|
| Secondary | Face, Legs, Activity, Cry, Consolability (FLACC) Scale Score | Post-Anesthesia Care Unit (PACU) nurses evaluated the patients using Face, Legs, Activity, Cry, Consolability (FLACC) Scale scores at 10 minutes post-op, 20 minutes post-op and at time of PACU discharge. Each category is scored as 0 (no indication of pain), 1 (indication of moderate pain), or 2 (visibly experiencing severe pain). Total scores range from 0 to 10, with higher scores indicating more pain. | This analysis includes participants who completed the study. | Posted | Mean | Standard Deviation | score on a scale | 10 minutes post-op, 20 minutes post-op, PACU discharge (up to 261 minutes) |
|
|
|
| Secondary | Post-Anesthesia Care Unit (PACU) Recovery Time | The duration of time that a participant was in the Post-Anesthesia Care Unit (PACU), following surgery, measured in minutes. | This analysis includes participants who completed the study. | Posted | Mean | Standard Deviation | minutes | Until PACU discharge (up to 261 minutes) |
|
|
|
| Secondary | Number of Participants With Post-Tonsillectomy Bleeding | Participants were monitored via medical chart review for post-tonsillectomy bleeding. | This analysis includes participants who completed the study. | Posted | Count of Participants | Participants | Up to 14 days after surgery |
|
|
|
| Secondary | Pain Medication Administration | The total amount of pain medications administered during hospitalization was examined. | This analysis includes participants who completed the study. | Posted | Mean | Standard Error | Morphine Equivalents in mg/kg | Surgery through hospital discharge (up to post-operative day 2) |
|
|
|
| 0 |
| 29 |
| 0 |
| 29 |
| 1 |
| 29 |
| EG001 | Standard of Care | Participants randomized to this group received the pain management standard of care for the adenotonsillectomy procedure. | 0 | 32 | 0 | 32 | 2 | 32 |
Not provided
Not provided
Not provided
| D020919 |
| Sleep Disorders, Intrinsic |
| D020920 | Dyssomnias |
| D012893 | Sleep Wake Disorders |
| D009422 | Nervous System Diseases |
| D011183 | Postoperative Complications |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D010146 | Pain |
| D009461 | Neurologic Manifestations |
| D012816 | Signs and Symptoms |
| D006571 | Heterocyclic Compounds |
| D019984 | Quality Indicators, Health Care |
| D011787 | Quality of Health Care |
| D006298 | Health Services Administration |
| D017530 | Health Care Quality, Access, and Evaluation |
| D008738 | Methyl Ethers |
| D004987 | Ethers |
| D009930 | Organic Chemicals |
| D006845 | Hydrocarbons, Fluorinated |
| D006846 | Hydrocarbons, Halogenated |
| D006838 | Hydrocarbons |
| D010636 | Phenols |
| D001555 | Benzene Derivatives |
| D006841 | Hydrocarbons, Aromatic |
| D006844 | Hydrocarbons, Cyclic |
| D001557 | Benzenesulfonates |
| D001190 | Arylsulfonates |
| D017739 | Arylsulfonic Acids |
| D013451 | Sulfonic Acids |
| D013456 | Sulfur Acids |
| D013457 | Sulfur Compounds |
| D007093 | Imidazoles |
| D001393 | Azoles |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D002227 | Carbazoles |
| D006575 | Heterocyclic Compounds, 3-Ring |
| D009022 | Morphine Derivatives |
| D009019 | Morphinans |
| D053610 | Opiate Alkaloids |
| D000470 | Alkaloids |
| D006572 | Heterocyclic Compounds, Bridged-Ring |
| D006576 | Heterocyclic Compounds, 4 or More Rings |
| D010616 | Phenanthrenes |
| D011084 | Polycyclic Aromatic Hydrocarbons |
| D011083 | Polycyclic Compounds |
| PACU discharge |
|